前列腺癌立体定向体部放疗:基于倾向性评分分析比较射波刀与容积旋转调强放疗的3年泌尿生殖系统毒性研究
本研究回顾性分析两家机构2017至2020年非转移性前列腺癌患者,经倾向性评分匹配提取70例,分别接受射波刀或容积旋转调强放疗(VMAT)的立体定向体部放疗(SBRT),总剂量36.25 Gy分5次连续5个工作日完成。射波刀组急性期(<3个月)国际前列腺症状评分(IPSS)峰值显著低于VMAT组(16.2 vs 20.2,p=0.025),治疗相关2级急性泌尿生殖系统毒性发生率有更低趋势(22.9% vs 45.7%,p=0.077)。
要点
- 射波刀组急性期IPSS峰值显著低于VMAT组(16.2 vs 20.2,p=0.025)。
- 2级急性泌尿生殖系统毒性射波刀组22.9% vs VMAT组45.7%(p=0.077),有更低趋势。
- 两组晚期IPSS、泌尿生殖系统毒性及全部阶段胃肠道毒性均无差异,未观察到≥3级毒性。
核心结论
- 无论采用哪种治疗方式,SBRT治疗前列腺癌均有效且无严重毒性,但射波刀在急性前列腺症状方面优于VMAT。
研究设计与样本
- 回顾性分析两家机构2017至2020年非转移性前列腺癌患者的病历资料。
- 基于年龄、治疗前国际前列腺症状评分(IPSS)和前列腺体积进行倾向性评分匹配,提取70例患者进行分析。
- 患者接受SBRT,总剂量36.25 Gy分5次、连续5个工作日完成,使用射波刀或容积旋转调强放疗(VMAT)。
主要发现
- 射波刀组低、中、高危患者分别为2例、19例、14例,VMAT组分别为4例、17例、14例。
- 两组中位随访时间均为3年;射波刀组1例死于无关原因,未观察到生化或临床复发、远处转移或前列腺癌死亡。
- 急性期(<3个月)IPSS峰值射波刀组显著低于VMAT组(16.2 vs 20.2,p=0.025)。
- 多因素回归分析中,治疗方式(p=0.03)、年龄(p=0.01)、放疗前膀胱用药(p=0.03)和新辅助雄激素剥夺治疗(p=0.04)影响急性期IPSS峰值。
- 治疗相关2级急性泌尿生殖系统毒性发生率射波刀组22.9% vs VMAT组45.7%(p=0.077),射波刀组有更低趋势;两组晚期IPSS、泌尿生殖系统毒性及全部阶段胃肠道毒性无差异,至今未观察到≥3级毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate whether the rate of stereotactic body radiation therapy-related (SBRT-related) genitourinary (GU) toxicity is lower in patients with prostate cancer treated with CyberKnife. METHODS: We retrospectively reviewed the medical records of patients with nonmetastatic prostate cancer at two institutions between 2017 and 2020. We analyzed 70 patients who were extracted by propensity score matching based on age, pre-treatment International Prostate Symptom Score (IPSS), and prostate volume. The patients were treated with SBRT, with a total dose of 36.25 Gy in five fractions over five consecutive weekdays, using CyberKnife or volumetric-modulated arc therapy (VMAT). RESULTS: The low-, medium-, and high-risk patients were 2, 19, and 14, respectively, in the CyberKnife group and 4, 17, and 14, respectively, in the VMAT group. The median follow-up time in both groups was 3 years. One patient with CyberKnife died of unrelated causes. No biochemical or clinical recurrence, distant metastases, or death from prostate cancer was observed. The peak values of IPSS in the acute phase (< 3 months) were significantly lower in the CyberKnife than in the VMAT group (CyberKnife:16.2 vs VMAT:20.2, p = 0.025). In multiple regression analyses, the treatment modality (p = 0.03), age (p = 0.01), bladder medication pre-irradiation (p = 0.03), and neoadjuvant androgen deprivation therapy (p = 0.04) contributed to the peak value of the acute-phase IPSS. The incidence of treatment-related grade 2 acute GU toxicity tended to be lower in the CyberKnife than the VMAT group (CyberKnife: 22.9% vs. VMAT: 45.7%, p = 0.077). No difference was noted between the groups with regard to late IPSS or GU toxicity and gastrointestinal toxicity in all phases. Toxicities of grade ≥ 3 have not been observed to date. CONCLUSIONS: Regardless of treatment modality, SBRT is effective in treating prostate cancer without serious toxicity. However, CyberKnife has an advantage over VMAT in terms of acute prostate symptoms.
引用
- Ito M, Yoshioka Y, Takase Y, et al. Stereotactic body radiation therapy for prostate cancer: a study comparing 3-year genitourinary toxicity between CyberKnife and volumetric-modulated arc therapy by propensity score analysis. Radiat Oncol. 2023. PMID: 36823674. doi:10.1186/s13014-023-02233-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。